title: Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
authors.forename: G
authors.initials: G
authors.lastname: Göhring
authors.forename: K
authors.initials: K
authors.lastname: Lange
authors.forename: W
authors.initials: W
authors.lastname: Hofmann
authors.forename: K V
authors.initials: KV
authors.lastname: Nielsen
authors.forename: E
authors.initials: E
authors.lastname: Hellström-Lindberg
authors.forename: L
authors.initials: L
authors.lastname: Roy
authors.forename: M
authors.initials: M
authors.lastname: Morgan
authors.forename: H
authors.initials: H
authors.lastname: Kreipe
authors.forename: G
authors.initials: G
authors.lastname: Büsche
authors.forename: A
authors.initials: A
authors.lastname: Giagounidis
authors.forename: B
authors.initials: B
authors.lastname: Schlegelberger
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D018450:Disease Progression; D006801:Humans; D000077269:Lenalidomide; D009190:Myelodysplastic Syndromes / Q000188:drug therapy / Q000235:genetics*; D016615:Telomere; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide